SCHEMBL27306933

SCHEMBL27306933

CCC1(C)Nc2c(Cl)cc(Nc3ccccc3)cc2C(C)=C1C

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK13 O15264 1/20 0.33
▸ MAPK12 P53778 1/20 0.33
▸ MAPK11 Q15759 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ MGAT2 Q10469 3/20 0.32
▸ MGAT1 P26572 2/20 0.32
▸ MGAT3 Q09327 1/20 0.32
▸ APP P05067 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HPGD P15428 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ STK10 O94804 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ SLK Q9H2G2 1/20 0.31
▸ LMNA P02545 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27306826 0.88 NPSR1 (0.33) MGAT2MGAT1MGAT3APPNPSR1
SCHEMBL27306821 0.83 STK10 (0.36) MGAT2MGAT1MGAT3APPNPSR1
SCHEMBL27307055 0.83 MGAT1 (0.31) MGAT2MGAT1MGAT3APPNPSR1
SCHEMBL27306369 0.75 APP (0.32) MAPK13MAPK12MAPK11MAPK14APP
SCHEMBL27305898 0.74 ALDH1A1 (0.42) MAPK13MAPK12MAPK11MAPK14APP
SCHEMBL27306928 0.72 EGFR (0.38) MGAT2MGAT1MGAT3NPSR1HPGD
SCHEMBL27307388 0.71 HTT (0.33) MEN1KMT2AMAPTHSD17B10
SCHEMBL27307391 0.70 ALDH1A1 (0.39) HPGDMEN1KMT2ALMNAMAPT
SCHEMBL27307053 0.68 MEN1 (0.31) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL27307057 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023235855-A1 QUINOLINEAMINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF FLEXSYS AMERICA L.P. (US) 2023-12-07 — — WO disclosed
Send feedback